Cambridge, MA, May 5, 2014 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the Human Proteome Organization (HUPO) are delighted to announce HUPO's affiliation with Elsevier's new, open access journal, Translational Proteomics.
HUPO is an international scientific organization that represents and promotes proteomics through worldwide cooperation and collaborations. HUPO plays an essential role in the development and implementation of standards and policies in proteomics research as well as determining how proteins play a role in human health and disease.
As such, Elsevier is delighted that its open access journal Translational Proteomics can fill an important need for the organization helping them with the dissemination of translational discoveries.
Translational Proteomics covers all areas of human proteomics using multi-disciplinary approaches to untangle complex disease processes. The journal emphasizes linking basic proteomic sciences to clinical research, from patient to bench to bedside, an important component of proteomics research that the HUPO embraces.
"HUPO is very pleased to provide its membership with significant benefits from this new collaboration with Translational Proteomics and Elsevier and we look forward to a long and fruitful relationship," explains Maxey C.M. Chung, HUPO Secretary General.
"We are really excited about this new collaboration with HUPO", says Jean-Charles Sanchez, Editor-in-Chief of Translational Proteomics. "Both HUPO and Translational Proteomics aim to cover and disseminate knowledge across all areas of human proteomics using multi-disciplinary approaches to untangle complex disease processes. The journal provides space for publications of the Biology/Disease Human Proteome Project (HPP) initiatives."
Elsevier will also annually sponsor the 'HUPO Translational Proteomics Award'. The award is in recognition of a scientist for distinguished scientific achievements in the field of Translational Proteomics and will be awarded at the annual HUPO meeting.
HUPO members will receive 25% discount on the open access author fees when their articles are published in Translational Proteomics.
The Human Proteome Organization (HUPO) is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training. HUPO's mission is to define and promote proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training to better understand human disease.
About Translational Proteomics
Translational Proteomics covers all areas of human proteomics using multi-disciplinary approaches to untangle complex disease processes. Emphasis is placed on linking basic sciences to clinical research (from patient to bench to bedside). It focuses on the rapid dissemination of novel discoveries. Topics included, but not limited to, are: Translational Systems Biology and Integrative Bioinformatics; Clinical Proteomics and Personalized medicine; Comparative proteomics and drug development; Medical bioinformatics and biostatistics; Biomarkers; Food and Health. For more information, go to: http://www.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 617 397 2882